June 3, 2020
After many years of exciting preclinical developments, many companies are now bringing investigational products for rare neuromuscular disorders to clinical trials. Clinical trials about rare neuromuscular disorders are more challenging than more common diseases, in part due to how these disorders are diagnosed.
Many rare neuromuscular disorders have genetic causes, such as spinal muscular atrophy (SMA) or Duchenne muscular dystrophy (DMD). Correct interpretation of diagnostic genetic test results is an essential part of confirming that every clinical trial participant is truly eligible for the trial. Sub – types are often defined by specific genetic findings. While trial sites may have access to eligible participants, they may lack the resources to navigate this difficult process efficiently.
TRiNDS offers central genetic confirmation services to clients conducting clinical trials and research studies in rare neuromuscular disorders. Our licensed genetic counselors review the genetic test reports to provide consistent review and analysis of test results across sites. These reviews confirm that each participant meets all the eligibility criteria prior to randomization and that genetic test results are entered consistently into study databases. Centralized expert supports help your sites comply with your study protocol efficiently and consistently. Contact us to request a quote for genetic confirmation services.